BHVN Biohaven Pharmaceutical Holding Co Ltd

$15.66

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The company is headquartered in New Haven, Connecticut.

Website: https://www.biohaven.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1935979
Address
215 CHURCH STREET, NEW HAVEN, CT, US
Valuation
Market Cap
$2.08B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
4.91
Performance
EPS
$-9.28
Dividend Yield
—
Profit Margin
0.00%
ROE
-198.80%
Technicals
50D MA
$29.67
200D MA
$39.03
52W High
$55.70
52W Low
$15.79
Fundamentals
Shares Outstanding
102M
Target Price
$61.00
Beta
4.15

BHVN EPS Estimates vs Actual

● Estimated
● Actual

BHVN News & Sentiment

Aug 22, 2025 • Benzinga NEUTRAL
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - Biohaven ( NYSE:BHVN ) , Centene ( NYSE:CNC )
BENSALEM, Pa., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Aug 22, 2025 • Benzinga NEUTRAL
Why Is Biohaven Stock Soaring Friday? - Biohaven ( NYSE:BHVN )
The FDA has cancelled the advisory meeting for Biohaven's SCA drug application. NDA decision for troriluzole expected in the fourth quarter of 2025. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → Biohaven Ltd.
Aug 22, 2025 • Benzinga NEUTRAL
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHVN - ( BHVN )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. BHVN between March 24, 2023 and May 14, 2025, both dates inclusive ( the "Class Period" ) , of the important September 12, 2025 lead ...
Aug 21, 2025 • Benzinga NEUTRAL
DEADLINE ALERT for BHVN and NEOG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Biohaven ( NYSE:BHVN ) , Neogen ( NASDAQ:NEOG )
LOS ANGELES, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Aug 20, 2025 • Benzinga NEUTRAL
Deadline Alert: Biohaven Ltd. ( BHVN ) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Biohaven ( NYSE:BHVN )
LOS ANGELES, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. ( "Biohaven" or the ...
Aug 20, 2025 • Benzinga NEUTRAL
BHVN Investors Have the Opportunity to Lead the Biohaven Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Biohaven ( NYSE:BHVN )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options
Sentiment Snapshot

Average Sentiment Score:

-0.055
50 articles with scored sentiment

Overall Sentiment:

Neutral

BHVN Reported Earnings

Mar 03, 2025
Dec 31, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $-1.71
  • Estimate: $-1.47
  • Whisper: —
  • Surprise %: -16.2%
Nov 13, 2024
Sep 30, 2024 (Pre market)
-0.19 Surprise
  • Reported EPS: $-1.74
  • Estimate: $-1.55
  • Whisper: —
  • Surprise %: -12.2%
Aug 09, 2024
Jun 30, 2024 (Pre market)
-1.8 Surprise
  • Reported EPS: $-3.50
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: -106.2%
May 09, 2024
Mar 31, 2024 (Post market)
-0.63 Surprise
  • Reported EPS: $-2.20
  • Estimate: $-1.57
  • Whisper: —
  • Surprise %: -40.1%
Feb 29, 2024
Dec 31, 2023 (Post market)
-0.4 Surprise
  • Reported EPS: $-1.81
  • Estimate: $-1.41
  • Whisper: —
  • Surprise %: -28.4%
Nov 14, 2023
Sep 30, 2023 (Post market)
-0.16 Surprise
  • Reported EPS: $-1.50
  • Estimate: $-1.34
  • Whisper: —
  • Surprise %: -11.9%
Jul 31, 2023
Jun 30, 2023 (Pre market)
-0.11 Surprise
  • Reported EPS: $-1.32
  • Estimate: $-1.21
  • Whisper: —
  • Surprise %: -9.1%
May 12, 2023
Mar 31, 2023 (Post market)
0.38 Surprise
  • Reported EPS: $-1.03
  • Estimate: $-1.41
  • Whisper: —
  • Surprise %: 26.9%
Mar 23, 2023
Dec 31, 2022 (Post market)
-2.1 Surprise
  • Reported EPS: $-3.32
  • Estimate: $-1.22
  • Whisper: —
  • Surprise %: -172.1%

Financials